Mar 28, 2023 / 01:15PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Good morning, everybody. I'm very excited, and it's appropriate that the first panel of our CNS conference this year is with Biogen's Head of Development, Priya Singhal. So thank you, Priya, very much, for joining me again this year. It was a great discussion last year, and now I have a whole page-and-a-half of questions written out. I'm hoping we can try to get to as much as possible. For everybody joining, you can always feel free to shoot me a note if there are any specific questions you want me to ask, there also should be a link in the webcast for you to type in any questions. But maybe we can start and have a fulsome discussion on Alzheimer's, Priya, and thank you, again.
Questions and Answers:
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior AnalystI think one interesting topical question is related to the lecanemab Ad
Trustpilot
